Pharmaceutical

Filter

Current filters:

None

Popular Filters

6776 to 6800 of 7149 results

US Court dismisses whistleblower case against Millennium Labs

05-02-2012

US District Court Judge Joseph Tauro has ordered the complete dismissal of a whistleblower law suit against…

LegalMillennium LaboratoriesNorth AmericaPharmaceuticalResearch

Clopidogrel with aspirin does not prevent more small strokes

05-02-2012

The anti-blood clot regimen that adds the drug clopidogrel (French drug major Sanofi’s blockbuster…

AspirinCardio-vascularClopidogrelPharmaceuticalPlavixResearchSanofi

EMA planning fundamental change in pharmacovigilance rules

03-02-2012

The European Medicines Agency, together with the European Union member states and the European Commission,…

BiotechnologyEuropePharmaceuticalRegulation

Merck & Co back in profit, beats forecasts

03-02-2012

US drug giant Merck & Co (NYSE: MRK) has posted fourth-quarter and full-year 2011 results, with 4th-qtr…

FinancialMerck & CoPharmaceutical

Victoza sales boost Novo Nordisk

03-02-2012

Danish insulin giant Novo Nordisk (NVO: N) yesterday reported full-year 2011 sales of 66.35 billion Danish…

DiabetesFinancialNovo NordiskPharmaceuticalVictoza

2011 financial briefs for Alkermes, Allergan, Gilead and Vertex

03-02-2012

Among the plethora of financial results being reported by US biotech and pharmaceutical companies were…

AlkermesAllerganBiotechnologyFinancialGilead SciencesPharmaceuticalVertex

Strong international drug sales drive Ipsen 2011

03-02-2012

French drugmaker Ipsen (Euronext: IPN) reported that, in full-year 2011, group drug sales grew by 5.7%…

FinancialIpsenPharmaceutical

Sucampo’s OBD drug meets Ph III endpoint

02-02-2012

USA-based Sucampo Pharmaceuticals (Nasdaq: SCMP) and Japanese drug major Takeda Pharmaceuticals’…

Gastro-intestinalsLubiprostonePharmaceuticalResearchSucampoTakeda Pharmaceuticals

European thrombosis market in urgent need for enhanced products, says F&S

02-02-2012

The increasing incidence of thrombosis, paralleled by the maturing life cycles of existing products,…

Cardio-vascularEuropeMarkets & MarketingPharmaceuticalResearch

NICE issues negative guidance for Zytiga

02-02-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued new draft…

EuropeJanssenJohnson & JohnsonOncologyPharmaceuticalPricingRegulationZytiga

AstraZeneca profits rise, but more jobs to go

02-02-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning unveiled a set of financial results for…

AstraZenecaFinancialPharmaceutical

Shire partners with Sangamo for hemophilia and other diseases

02-02-2012

Ireland-headquartered specialty pharma company Shire plc (LSE: SHP) has entered into a collaboration…

LicensingPharmaceuticalRare diseasesSangamo BioSciencesShire

UCB links with Astellas for Cimzia in Japan

02-02-2012

Following the recent discontinuation of a commercialization accord for its rheumatoid arthritis drug…

Anti-Arthritics/RheumaticsAsia-PacificAstellas PharmaCimziaLicensingPharmaceuticalUCB

Costs take toll on earnings from Japan’s Takeda

01-02-2012

Japan’s largest drugmaker, Takeda Pharmaceutical (TSE: 4502), yesterday released consolidated results…

FinancialNycomedPharmaceuticalTakeda Pharmaceuticals

Spectrum in-licenses novel GCSF drug from Hanmi Pharma

01-02-2012

USA-based Spectrum Pharmaceuticals (NasdaqGS: SPPI) has entered into a co-development and commercialization…

Hanmi PharmaceuticalLicensingOncologyPharmaceuticalSpectrum Pharmaceuticals

Impax buys US rights to Zomig

01-02-2012

Impax Pharmaceuticals, the branded products business unit of Impax Laboratories (Nasdaq: IPXL) has licensed…

AstraZenecaImpax LaboratoriesLicensingMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalZomig

Janssen drops deal with Orexo for OX-CLI/OX-ESI

01-02-2012

US health care major Johnson & Johnson INYSE: JNJ) subsidiary Janssen has decided to end research collaboration…

FinancialJanssenJohnson & JohnsonLicensingOrexo ABPharmaceuticalRespiratory and Pulmonary

Global osteoporosis market report sees strong showing in China

01-02-2012

The global market for drugs to treat osteoporosis was estimated to be worth $7.3 billion in 2010 and…

AmgenAnti-Arthritics/RheumaticsAsia-PacificGlobalMarkets & MarketingPharmaceuticalXgeva

FDA approves combo diabetes drug Jentadueto and Kalydeco

01-02-2012

The US Food and Drug Administration) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets,…

Boehringer IngelheimDiabetesEli LillyJentaduetoKalydecolinagliptinNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Pfizer’s fourth-quarter net income slumps 50%

01-02-2012

Global drug behemoth Pfizer (NYSE: PFE) reported fourth-quarter 2011 net income of $1.4 billion, a year-on-year…

FinancialPfizerPharmaceutical

Roche posts strong 2011 profits, upbeat on 2012

01-02-2012

Swiss drug major Roche (ROG: SIX) this morning announced that group sales for the full-year 2011 grew…

FinancialPharmaceuticalRoche

Eli Lilly results hammered by Zyprexa patent loss

01-02-2012

US drug major Eli Lilly (NYSE: LLY) said that fourth-quarter 2011 global sales dropped 2% to $6.05 billion.…

Eli LillyFinancialPharmaceutical

6776 to 6800 of 7149 results

Parexel

Parexel

Back to top